PL1919465T3 - Inhibitory GSK-3 - Google Patents

Inhibitory GSK-3

Info

Publication number
PL1919465T3
PL1919465T3 PL06776492T PL06776492T PL1919465T3 PL 1919465 T3 PL1919465 T3 PL 1919465T3 PL 06776492 T PL06776492 T PL 06776492T PL 06776492 T PL06776492 T PL 06776492T PL 1919465 T3 PL1919465 T3 PL 1919465T3
Authority
PL
Poland
Prior art keywords
gsk
inhibitors
Prior art date
Application number
PL06776492T
Other languages
English (en)
Inventor
Ana MARTÍNEZ GIL
Miguel Medina Padilla
Mercedes Alonso Cascón
Ana Fuertes Huerta
María Luisa NAVARRO RICO
María José PÉREZ PUERTO
Ana Castro Morera
Ester MARTÍN APARICIO
Original Assignee
Asd Therapeutics Partners Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asd Therapeutics Partners Llc filed Critical Asd Therapeutics Partners Llc
Publication of PL1919465T3 publication Critical patent/PL1919465T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
PL06776492T 2005-07-29 2006-07-28 Inhibitory GSK-3 PL1919465T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05380176A EP1749523A1 (en) 2005-07-29 2005-07-29 GSK-3 inhibitors
PCT/EP2006/007520 WO2007017145A2 (en) 2005-07-29 2006-07-28 Gsk-3 inhibitors
EP06776492.8A EP1919465B1 (en) 2005-07-29 2006-07-28 Gsk-3 inhibitors

Publications (1)

Publication Number Publication Date
PL1919465T3 true PL1919465T3 (pl) 2018-06-29

Family

ID=35445902

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06776492T PL1919465T3 (pl) 2005-07-29 2006-07-28 Inhibitory GSK-3

Country Status (23)

Country Link
US (1) US8686042B2 (pl)
EP (2) EP1749523A1 (pl)
JP (1) JP5484726B2 (pl)
KR (1) KR101471999B1 (pl)
CN (1) CN101257900B (pl)
AU (1) AU2006278829B2 (pl)
BR (1) BRPI0615968B1 (pl)
CA (1) CA2616451C (pl)
CY (1) CY1119971T1 (pl)
DK (1) DK1919465T3 (pl)
ES (1) ES2661326T3 (pl)
HR (1) HRP20180109T1 (pl)
HU (1) HUE036844T2 (pl)
IL (1) IL189048A (pl)
LT (1) LT1919465T (pl)
NO (1) NO341454B1 (pl)
NZ (1) NZ566380A (pl)
PL (1) PL1919465T3 (pl)
PT (1) PT1919465T (pl)
RU (1) RU2449998C2 (pl)
SI (1) SI1919465T1 (pl)
WO (1) WO2007017145A2 (pl)
ZA (1) ZA200800983B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008046919A2 (en) 2006-10-21 2008-04-24 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
MX2010008706A (es) * 2008-02-06 2010-08-30 Noscira Sa Derivados de fenil-prenilo, de origen marino y sintetico. para el tratamiento de enfermedades o trastornos cognitivos, neurodegenerativos o neuronales.
EP2262498A2 (en) * 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
ES2418457T3 (es) * 2008-04-24 2013-08-13 Abbott Gmbh & Co. Kg Derivados de 1-(7-(hexahidropirrolo[3,4-c]pirrol-2(1H)-il)quinolin-4-il)-3-(pirazin-2-il)urea y compuestos relacionados como inhibidores de glucógeno sintasa cinasa 3 (GSK-3)
GEP20207129B (en) 2009-06-17 2020-07-10 Vertex Pharma Inhibitors of influenza viruses replication
US9266855B2 (en) 2010-09-27 2016-02-23 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP2854539A4 (en) * 2012-05-14 2016-03-09 Univ Kansas PHOSPHONATE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER
BR112015023261A2 (pt) 2013-03-14 2017-07-18 Massachusetts Inst Technology composições e métodos para expansão e cultura de células-tronco epiteliais
PT3068776T (pt) 2013-11-13 2019-08-26 Vertex Pharma Inibidores da replicação de vírus da gripe
HUE038820T2 (hu) 2013-11-13 2018-11-28 Vertex Pharma Eljárás influenzavírusok replikációjának inhibitorai elõállítására
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
CN106727556B (zh) * 2016-11-30 2017-10-20 鑫喆喆 一种治疗脑损伤的药物组合物
AU2017386417B2 (en) 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
WO2020037323A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN117186027B (zh) * 2023-09-11 2024-04-19 上海蓝木化工有限公司 一种糖原合酶激酶-3抑制剂及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB895625A (en) * 1957-12-27 1962-05-02 Hoechst Ag New benzene-sulphonyl benzyl-ureas and process of preparing them
ES474449A1 (es) * 1978-10-23 1979-05-01 Invest Tecnica Aplicada Procedimiento de obtencion de ureas y tioureas con actividad farmacologica.
DE3371508D1 (en) * 1983-01-24 1987-06-19 Duphar Int Res Benzoylurea compounds, and pesticidal and pharmaceutical compositions comprising same
JPH10182588A (ja) * 1996-10-30 1998-07-07 Ss Pharmaceut Co Ltd 置換ベンジル尿素誘導体及びこれを含有する医薬
US5922767A (en) * 1996-10-30 1999-07-13 Ss Pharmaceutical Co., Ltd. Substituted benzylurea derivatives and medicine containing the same
US6071934A (en) * 1997-03-25 2000-06-06 Cell Pathways, Inc. Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
NZ504124A (en) * 1997-11-07 2002-10-25 Schering Corp Phenyl-alkyl-imidazoles and use in treating inflammatory disease
PE20000942A1 (es) * 1998-07-31 2000-09-28 Lilly Co Eli Derivados de amida, carbamato y urea
EP1274415A4 (en) * 2000-03-14 2005-09-07 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
WO2002029091A2 (en) * 2000-10-02 2002-04-11 Reddy Us Therapeutics, Inc. Methods and compositions for the treatment of inflammatory diseases
SE0102440D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compound
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102438D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
AR039209A1 (es) * 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
SE0201194D0 (sv) * 2002-04-19 2002-04-19 Astrazeneca Ab New compounds
EP2573079A3 (en) * 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
EP1493438A1 (en) * 2003-07-03 2005-01-05 Bayer HealthCare AG Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
EP1586318A1 (en) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors

Also Published As

Publication number Publication date
LT1919465T (lt) 2018-04-10
WO2007017145A3 (en) 2007-04-26
HUE036844T2 (hu) 2018-08-28
EP1749523A1 (en) 2007-02-07
CA2616451A1 (en) 2007-02-15
RU2449998C2 (ru) 2012-05-10
BRPI0615968B1 (pt) 2023-10-03
AU2006278829A1 (en) 2007-02-15
BRPI0615968A2 (pt) 2011-05-31
IL189048A (en) 2017-04-30
JP2009502846A (ja) 2009-01-29
NZ566380A (en) 2011-01-28
SI1919465T1 (en) 2018-04-30
US20090124686A1 (en) 2009-05-14
EP1919465B1 (en) 2017-12-27
CN101257900A (zh) 2008-09-03
AU2006278829B2 (en) 2012-03-29
CA2616451C (en) 2015-01-20
HRP20180109T1 (hr) 2018-04-20
US8686042B2 (en) 2014-04-01
WO2007017145A2 (en) 2007-02-15
IL189048A0 (en) 2008-08-07
ZA200800983B (en) 2009-07-29
NO341454B1 (no) 2017-11-13
RU2008107733A (ru) 2009-09-10
HK1124761A1 (zh) 2009-07-24
JP5484726B2 (ja) 2014-05-07
NO20081052L (no) 2008-02-28
KR101471999B1 (ko) 2014-12-10
DK1919465T3 (en) 2018-02-05
PT1919465T (pt) 2018-03-07
EP1919465A2 (en) 2008-05-14
CY1119971T1 (el) 2018-12-12
CN101257900B (zh) 2012-09-12
KR20080031440A (ko) 2008-04-08
ES2661326T3 (es) 2018-03-28

Similar Documents

Publication Publication Date Title
IL189048A0 (en) Gsk-3 inhibitors
IL178125A0 (en) Gsk-3 inhibitors
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
SI2383271T1 (sl) Aminokinoloni kot inhibitorji gsk-3
PT2264043T (pt) Inibidores de pan-selectina heterobifuncionais
IL190078A0 (en) Kinase inhibitors
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
ZA200802867B (en) Fap inhibitors
IL179398A0 (en) Dpp-ib inhibitors
GB201000648D0 (en) Phosphodiesterase 10 inhibitors
IL189112A0 (en) NOVEL HETEROCYCLIC NF-kB INHIBITORS
EP1856040A4 (en) NEW LIPOXYGENASE INHIBITORS
PL1943243T3 (pl) Inhibitory kinazy
ZA200805386B (en) MIF inhibitors
IL188850A0 (en) Cathepsin k inhibitors
ZA200800365B (en) Substituted tetrahydroqulnolines
GB0421355D0 (en) Inhibitors
GB0515327D0 (en) Comt inhibitors
GB0421356D0 (en) Inhibitors
GB0516967D0 (en) Inhibitors
GB0506443D0 (en) Novel inhibitors
ZA200711069B (en) HCV inhibitors
GB0524433D0 (en) Contents-relating arrangements
GB0503644D0 (en) Catstep I